events and are not a guarantee of future performance.
Furthermore, these statements are, by their nature, subject to a number of
risks and uncertainties that could cause actual performance and results to
differ materially from those discussed in the forward-looking statements as
a result of a number of factors. Further information regarding these and
other risks is included in Simcere's filing with the U.S. Securities and
Exchange Commission at
http://www.sec.gov . Simcere does not undertake any
obligation to update any forward-looking statement, except as required
under applicable law.
Conference Call
Simcere Pharmaceutical Group will host a conference call to discuss the
second quarter 2008 earnings on Tuesday, August 5, at 8 a.m. Eastern Time
(Tuesday, August 5 at 8 p.m. Beijing/Hong Kong time). The management team
will be on the call to discuss quarterly results and highlights and to
answer questions.
To access the conference call, please dial:
United States toll-free dial-in number: + 1 866 510 0704
United States dial-in number: + 1 617 597 5362
China toll-free dial-in number: +86 10 800 130 0399
Hong Kong dial-in number: +852 3002 1672
Please ask to be connected to Simcere's second quarter 2008 earnings
call and provide the following passcode: 25912661. Simcere also will
broadcast a live audio webcast of the conference call. The broadcast will
be available by visiting the ''Investor Relations'' section of the
Company's Web site at http://www.simcere.com .
Following the earnings conference call, an archive of the call will be
available by dialing:
United States toll-free dial-in number: +1 888 286 8010
International dial-in number: +1 617 801 6888
The passcode for replay participants is: 83949361. The tele
'/>"/>
SOURCE Simcere Pharmaceutical Group Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine news :1.
Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.2.
Simcere Pharmaceutical Group Reports Third Quarter 2007 Results3.
Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 20084.
Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results5.
Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China6.
Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 20087.
Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.8.
Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin9.
Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business10.
Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference11.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)